• Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

Exited investments

Home / Portfolio companies / Exited investments

RetroSense Therapeutics

RetroSense Therapeutics (Michigan, USA) is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions. RetroSense’s approach creates photosensitivity in retinal ganglian cells via channelrhodopsin-2 expression restoring vision irrespective of which gene defect is responsible for vision loss. The company has successfully finished Ph1 clinical trials. Allergan (NYSE: AGN) acquired RetroSense Therapeutics in 2016 for a total consideration of $555M (including milestone payments).

Bonti

Bonti (California, USA) is a rapidly growing biotechnology company engaged in the development of novel botulotoxin-based treatments. Bonti was founded by world-class experts with a proven success story at Allergan, one of the Fortune 500 fastest growing pharma companies having Botox™ as part of its product pipeline. The team has extensive neurotoxin, aesthetic and pain expertise, and is well-qualified to develop new treatment paradigms based on the novel neurotoxin platform and bring them to both aesthetic and therapeutic markets. The company was acquired by Allergan (NYSE: AGN) in Q4 2018 for $195M upfront plus undisclosed milestone payments.

Not disclosed

An undisclosed investment, this clinical-stage company in the UK is developing a drug against a severe CNS disorder based on research from one of the top universities.

News

13
oct

Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

More
25
jun

Pipeline Therapeutics Appoints Scott Oross as General Counsel

More
23
jun

Immusoft Announces Formation Of Scientific Advisory Board

More